Kwality Pharmaceuticals (539997) Q4 24/25 earnings summary

Executive summary

• Consolidated revenue for Q4FY25 rose 37% sequentially to ₹115.7 crore, with EBITDA up 52% to ₹26.6 crore, reflecting strong operational leverage and cost control initiatives.

• FY25 consolidated revenue grew 20.5% year-over-year to ₹370 crore, and EBITDA reached ₹82.31 crore, with margins improving to approximately 23%.

• Net profit after tax for FY25 was ₹39.8 crore (consolidated), up from ₹23.6 crore in FY24; EPS for FY25 was ₹38.36 versus ₹22.76 in FY24.

• Expansion into highly regulated markets, new product launches, and regulatory approvals in multiple geographies supported growth.

Financial highlights

• Q4FY25 consolidated revenue: ₹115.7 crore (up 37% QoQ); EBITDA: ₹26.6 crore (up 52% QoQ); EBITDA margin: ~23%.

• FY25 consolidated revenue: ₹370.2 crore (up 20.5% YoY); EBITDA: ₹82.3 crore; net profit: ₹39.8 crore.

• Standalone net profit for FY25: ₹39.9 crore; total comprehensive income: ₹39.8 crore.

• Receivables as of March 31, 2025: ₹154 crore, with one-third realized post year-end; inventory days improved to 82 from 98 YoY.

• Cash and cash equivalents (consolidated): ₹12.0 crore as of March 31, 2025, up from ₹2.3 crore last year.

Outlook and guidance

• FY26 revenue target set at ₹500 crore, with projected EBITDA margins in the 22–25% range.

• Anticipates further regulatory approvals and new product launches, including Azacitidine in Europe/UK and 10–15 new registrations in Mexico.

• Clinical trials for Erythropoietin to begin in FY26, with commercialization expected by Q3FY26.